BUZZ-Street View: Gilead's HIV injection has multi-billion peak sales potential

Reuters

Jun 20, 2025

BUZZ-Street View: Gilead's HIV injection has multi-billion peak sales potential

** The U.S. Food and Drug Administration on Wednesday approves Gilead Sciences GILD.O lenacapavir branded as Yeztugo, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus.

** Median PT of brokerages covering GILD is $118.50 - data compiled by LSEG

EXPECTING STRONG UPTAKE IN 2026

** J.P.Morgan ("overweight") continues to see room for further upside for shares with Yeztugo well positioned for a strong launch in PrEP and numerous HIV treatment combos advancing

** Mizuho ("outperform", PT:$117) says Yeztugo could potentially open the market, over time, to additional populations beyond the currently estimated 1.2 million to 2.25 million eligible consumers

** Oppenheimer ("outperform", PT:$125) thinks that adoption into more commercially mainstream markets will be needed to realize Yeztugo's full potential

** TD Cowen ("buy", PT:$110) sees multi-billion dollar peak sales potential for Yeztugo and says patient adherence to GILD's drug will be around 80% compared to 50% to 55% adherence rate seen with daily oral therapies

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2544121710"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544121710\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544121710?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-20 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544121710","market":"us","top_or_hot":-1,"title":"BUZZ-Street View: Gilead's HIV injection has multi-billion peak sales potential","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: Gilead's HIV injection has multi-billion peak sales potential</title></head><body><p>** The U.S. Food and Drug Administration on Wednesday approves Gilead Sciences <span>GILD.O</span> lenacapavir branded as Yeztugo, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus.</p><p>** Median PT of brokerages covering GILD is $118.50 - data compiled by LSEG</p><p>EXPECTING STRONG UPTAKE IN 2026</p><p>** J.P.Morgan (\"overweight\") continues to see room for further upside for shares with Yeztugo well positioned for a strong launch in PrEP and numerous HIV treatment combos advancing</p><p>** Mizuho (\"outperform\", PT:$117) says Yeztugo could potentially open the market, over time, to additional populations beyond the currently estimated 1.2 million to 2.25 million eligible consumers</p><p>** Oppenheimer (\"outperform\", PT:$125) thinks that adoption into more commercially mainstream markets will be needed to realize Yeztugo's full potential</p><p>** TD Cowen (\"buy\", PT:$110) <span>sees multi-billion dollar peak sales potential for Yeztugo</span> and says patient adherence to GILD's drug will be around 80% compared to 50% to 55% adherence rate seen with daily oral therapies</p><p>(Reporting by Christy Santhosh)</p><p>((Christy.Santhosh@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Street View: Gilead's HIV injection has multi-billion peak sales potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Street View: Gilead's HIV injection has multi-billion peak sales potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-20 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: Gilead's HIV injection has multi-billion peak sales potential</title></head><body><p>** The U.S. Food and Drug Administration on Wednesday approves Gilead Sciences <span>GILD.O</span> lenacapavir branded as Yeztugo, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus.</p><p>** Median PT of brokerages covering GILD is $118.50 - data compiled by LSEG</p><p>EXPECTING STRONG UPTAKE IN 2026</p><p>** J.P.Morgan (\"overweight\") continues to see room for further upside for shares with Yeztugo well positioned for a strong launch in PrEP and numerous HIV treatment combos advancing</p><p>** Mizuho (\"outperform\", PT:$117) says Yeztugo could potentially open the market, over time, to additional populations beyond the currently estimated 1.2 million to 2.25 million eligible consumers</p><p>** Oppenheimer (\"outperform\", PT:$125) thinks that adoption into more commercially mainstream markets will be needed to realize Yeztugo's full potential</p><p>** TD Cowen (\"buy\", PT:$110) <span>sees multi-billion dollar peak sales potential for Yeztugo</span> and says patient adherence to GILD's drug will be around 80% compared to 50% to 55% adherence rate seen with daily oral therapies</p><p>(Reporting by Christy Santhosh)</p><p>((Christy.Santhosh@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nL4N3SN0NV:1","article_id":"2544121710","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544121710","pubTimestamp":1750419100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Street View: Gilead's HIV injection has multi-billion peak sales potential** The U.S. Food and Drug Administration on Wednesday approves Gilead Sciences GILD.O lenacapavir branded as Yeztugo, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus.** Median PT of brokerages covering GILD is $118.50 - data compiled by LSEGEXPECTING STRONG UPTAKE IN 2026** J.P.Morgan  continues to see room for further upside for shares with Yeztugo well positioned for a strong launch in PrEP and numerous HIV treatment combos advancing** Mizuho  says Yeztugo could potentially open the market, over time, to additional populations beyond the currently estimated 1.2 million to 2.25 million eligible consumers** Oppenheimer  thinks that adoption into more commercially mainstream markets will be needed to realize Yeztugo's full potential** TD Cowen  sees multi-billion dollar peak sales potential for Yeztugo and says patient adherence to ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"BUZZ-Street View：吉利德的HIV注射剂具有数十亿美元的峰值销售潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"BUZZ-Street View: Gilead's HIV injection has multi-billion peak sales potential** The U.S. Food and Drug Administration on Wednesday approves Gilead Sciences GILD.O lenacapavir branded as Yeztugo, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus.** Median PT of brokerages covering GILD is $118.50 - data compiled by LSEGEXPECTING STRONG UPTAKE IN 2026** J.P.Morgan (\"overweight\") continues to see room for further upside for shares with Yeztugo well positioned for a strong launch in PrEP and numerous HIV treatment combos advancing** Mizuho (\"outperform\", PT:$117) says Yeztugo could potentially open the market, over time, to additional populations beyond the currently estimated 1.2 million to 2.25 million eligible consumers** Oppenheimer (\"outperform\", PT:$125) thinks that adoption into more commercially mainstream markets will be needed to realize Yeztugo's full potential** TD Cowen (\"buy\", PT:$110) sees multi-billion dollar peak sales potential for Yeztugo and says patient adherence to GILD's drug will be around 80% compared to 50% to 55% adherence rate seen with daily oral therapies(Reporting by Christy Santhosh)((Christy.Santhosh@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}